Abstract Duffy antigen receptor for chemokines (DARC) binds to a number of pro-inflammatory chemokines, and since chemokines are known to regulate trafficking of osteoclast (OC) precursors, we predicted that DARC would regulate OC recruitment to sites of inflammation by modulating chemokine activity. To test this hypothesis, we evaluated the mRNA expression of Darc and the chemokines known to bind to DARC, in endothelial cells treated with bacterial lipopolysaccharide (LPS). The mRNA expression of Mcp-1, Rantes, Darc and Ccr5 was significantly increased in endothelial cells in response to LPS treatment. Blocking the function of DARC with neutralizing antibody partially abrogated the effect of LPS on the mRNA expression of Mcp-1 and Rantes. In vivo, mice with targeted disruption of Darc gene (Darc-KO) and control wild-type (WT) mice were used to assess the role of DARC in response to single LPS application on the top of parietal bones. Five hours post-LPS injection, local expression of Cd14 mRNA (a marker of inflammatory monocytes) was significantly increased in both lines of mice. However, the magnitude of increase was greater in WT mice compared with Darc-KO mice suggesting a role for DARC in mediating the recruitment of monocytes in response to LPS. Histological staining for tartrate-resistant acid phosphatase (TRAP) in calvaria sections taken from the injection sites revealed a significant reduction in TRAP-labeled surface per bone surface in response to LPS in Darc-KO mice compared with WT mice. Based on these findings, we concluded that DARC regulates recruitment of OC precursors at the inflammation site, probably through regulation of chemokines transcytosis across endothelial cell barrier.
Introduction
Chronic inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis and periodontitis most frequently lead to increased bone resorption [1] . Therefore, understanding the molecular pathways involved in the recruitment of osteoclast progenitors to the site of inflammation for subsequent bone resorption is crucial for the development of new therapeutic strategies to prevent or mitigate inflammation-induced bone loss. The infiltration of osteoclast precursors from blood circulation to the site of inflammation is a complicated process that involves adhesion molecules, proteolytic enzymes, cytokines and chemokines [2, 3] .
In our previous studies to identify new candidate genes that contribute to variation in peak bone mineral density (BMD), we have identified the Duffy Antigen Receptor for Chemokines (DARC) as a negative regulator of BMD. In these studies, it was found that lack of Darc expression led to reduced osteoclastic bone resorption, and increased BMD, in the Darc-knockout (KO) mice [4] . Furthermore, we recently reported that lack of Darc expression reduced post-fracture inflammation in mice [5] .
Darc is mainly expressed in erythrocytes and endothelial cells that are known for their importance in inflammation and wound healing. A study by Pruenster et al. [6] showed that DARC plays an important role in chemokine transcytosis through vascular endothelial cells (VEC) to regulate transendothelial migration of monocytes. Therefore, based on the predicted role of DARC in the transmigration of monocytes across VEC, and our previously published data on the role of DARC in regulating bone resorption and inflammation [4, 5] , we predicted that DARC would play a key role in mediating the effects of inflammatory chemokines on the control of transmigration of osteoclast precursors from vascular endothelium to the site of inflammation in bone.
Bacterial lipopolysaccharide (LPS) is known to induce the synthesis of the pro-inflammatory chemokines that bind to DARC, such as monocyte chemoattractant protein 1 and RANTES [7] . These two chemokines play important roles in osteoclastogenic leukocyte chemoattraction and bone loss [16, 18] . Thus, in the present study, we have examined the role of DARC-chemokine interaction in regulating the recruitment of osteoclast precursors. We induced an inflammatory response via local administration of LPS. Our results showed that DARC-chemokine interaction plays an important role in mediating LPS effect on the recruitment of osteoclast progenitors to the inflammatory site.
Materials and Methods

Animal Models
All animal experiments were approved by Institutional Animal Care and Use Committee at the VA Loma Linda Healthcare System and were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. C57BL/6J wild-type and Darc-knockout (KO) mice were used in the present study to determine the role of DARC on osteoclast precursor recruitment in response to local inflammation. Darc-KO and control wild-type (WT) mice were provided by Dr. A. Chaudhuri (Laboratory of Cell Biology, New York Blood Center, New York, NY, USA). The animals used in the present study were generated and bred as previously described by Luo et al. [8] and Edderkaoui et al. [4] .
Mice of 10-12 weeks old received a single 200 lg LPS (from Escherichia coli 055:B5; Sigma-Aldrich Corp., St. Louis, MO 63103, USA) subcutaneous injection on the top of calvaria at the midpoint between the two pinnae. Control animals received phosphate-buffered saline solution (PBS). Animals were then killed at three different time points to evaluate inflammatory cell recruitment and bone resorption markers at the PBS-and LPS-treated calvaria.
Cell Culture Assays
To assess the involvement of DARC on endothelial cell response to LPS challenge, we used a mouse SVEC4-10 cell line (ATCC, Manassas, VA 20110, USA; Catalog No. CRL-2181), an endothelial cell line derived from mouse axillary lymph node vessels. Cells were plated in six-well plates for 2 days and were grown in Dulbecco's modified Eagle's medium supplemented with 10 % fetal bovine serum (FBS) (Atlanta Biologicals, Inc., Flowery Branch, GA 30542, USA; Catalog No. S11150), 50 U/ml penicillin and 50 mg/ml streptomycin (Gibco/Thermo Fisher Scientific, Grand Island, NY 14072, USA; Catalog No. 15140-122). Upon reaching 50-70 % confluency, endothelial cells were treated with either 10 lg/ml LPS, or PBS, in DMEM supplemented with 0.5 % BSA for 6 and 24 h (hrs). For the 24-hour assay, either goat polyclonal anti-DARC antibody (Santa Cruz Biotechnology Inc., Paso Robles, CA 93446, USA) or IgG control was added to LPStreated cells to evaluate the involvement of DARC in response to LPS challenge.
RNA Extraction and Real-Time PCR
SVEC cells were harvested at 6 and 24 h after treatment with LPS or PBS and RNA isolated following the protocol provided with the RNeasy Mini Kit (Qiagen Inc., Valencia, CA 91355, USA; Catalog No. 74104). Mice treated with LPS/PBS were killed at 5 and 24 h post-LPS injection. Calvarial bone covering the injected area (6-10 mm diameter) was dissected out for RNA extraction using Trizol as per manufacturer's instructions (Life Technology Company; Ref# 15596018). Relative differences in mRNA expression between the groups were measured by real-time PCR using specific primers as previously described [5] . Briefly, reverse transcription was performed with MMLV Reverse Transcriptase (Promega, San Luis Obispo, CA, USA). Real-time PCR was performed using the SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) with gene-specific primers (Integrated DNA Technologies, Coralville, IA, USA). Changes in gene expression were determined by subtracting the Ct (threshold cycle) of target gene from the Ct value of the housekeeping gene, peptidylprolyl isomerase A (Ppia) (DCt = Ct of target gene -Ct of Ppia). Mean DCt of replicates was then used to calculate the difference in cycle thresholds between groups (DDCt). Then, the fold change was calculated as 2 -DDCt . The genes examined were as follows: interleukin (Il)-6, tumor necrosis factor a (Tnfa), monocyte chemotactic protein-1 (Mcp-1), regulated on activation normal T expressed and secreted (Rantes) also called Ccl5, Cd14, chemokine receptor (Ccr)1, Ccr2, Ccr5 and Darc.
Immunohistochemistry and TRAP Staining
Twenty-four and 72 h post-LPS or PBS injections, mice were killed and the entire calvarial bone was dissected, fixed in 10 % formalin and then decalcified using EDTA. The anterior half of the frontal bone and the interparietal as well as the occipital bone was trimmed off. The remaining calvarial bone was dehydrated in a graded series of alcohols, embedded in paraffin, and each sample sectioned at 5 lm thickness as described by Bancroft [9] and Li et al. [10] . Immunohistochemistry was performed using rat antimouse F4/80 (ABD Serotec, A Division of MorphoSys, Raleigh, NC 27609, USA) as previously described [5] , and cells were counterstained with hematoxylin [10] . Antigen detection was performed using DAB chromogenic staining (IHC WORLD, LLC, Ellicott City, MD 21042, USA; Catalog No. IW-1600B). Tartrate-resistant acid phosphatase (Trap) staining was performed as previously described [10] . Using a 209 microscope objective, 3-4 randomly selected fields within the sutures were analyzed for each section. Reproducibility in multiple sections from the same site was checked through the analysis of duplicates by two blinded independent observers. For F4/80, digital images were captured and analyzed using Image Pro Plus software (Media Cybernetics, Silver Spring, MD, USA). Data are expressed as the percentage of brownstained area/total field area and are presented as fold change between LPS-treated mice and PBS-treated WT mice. TRAP-stained surfaces were measured using OsteoMeasure software (Osteometrics Inc., GA, USA), and the data are expressed as TRAP-stained surface/bone surface [10] and are presented as percentage of PBS-treated samples from WT mice.
Statistical Analysis
For gene expression profiling, data were normalized relative to the housekeeping gene, peptidylprolyl isomerase A (Ppia), and data expressed as a fold change relative to WT samples treated with PBS ± standard error of mean (SEM) as previously described [5] . Histology data were expressed as the mean ± SEM and were reported as percentage of control PBS-treated samples. Mean differences were compared, and significant differences between groups from all the data were determined by Student's t test. Differences were considered significant at values of p B 0.05.
Results
In order to examine the role of DARC-chemokine interaction on local inflammation, we first evaluated the expression level of the chemokines that bind to DARC, as well as the expression of Darc gene and other chemokine receptors, in response to LPS treatment in vitro and in vivo. Treatment of SVEC mouse endothelial cells with LPS increased mRNA expression of two major pro-inflammatory cytokines: Il-6 and Tnfa, as compared to PBS-treated controls (Fig. 1a) . In response to a 6-h treatment with LPS, mRNA levels for Mcp-1 and Rantes, two inflammatory chemokines known to bind to DARC, were increased by 12-and threefold, respectively (Fig. 1b) . Evaluation of the expression levels of chemokine receptors in SVEC cells in response to LPS treatment revealed a 23-and 15-fold increase, respectively, in Ccr5 and Darc mRNA levels as compared to cells treated with vehicle alone (Fig. 1c) . While the expression level of Ccr2 remained unchanged, Ccr1 expression was increased slightly in response to 6-h LPS treatment in SVEC cells (Fig. 1c) . After a 24-h treatment with LPS treatment, the levels of Rantes and Mcp-1 mRNA remained elevated (Fig. 2a) , while those of the chemokine receptors, Ccr5 and Darc, returned to the levels observed prior to treatment (Fig. 2c) .
To determine whether DARC is involved in mediating changes in the expression levels of chemokines and their receptors in response to LPS treatment, we measured the levels of Il-6, Rantes, Mcp-1 and Ccr5 mRNAs in response to a 24-h LPS treatment, in the presence of either neutralizing antibody to DARC or control IgG. We found significant reductions in mRNA levels for Il-6 and Mcp-1, but not Rantes, in cells treated with LPS and DARC-Ab, as compared to cells treated with LPS and control IgG (Fig. 2) . However, no significant difference in mRNA expression of either Ccr5 or Darc was observed in cells treated with LPS and either DARC-Ab or control IgG (Fig. 2) .
To determine the role of DARC in mediating LPS effects on the expression levels of mediators of inflammatory response in vivo, we measured mRNA levels of genes encoding inflammatory cytokines, chemokines and their receptors after local LPS treatment in a mouse calvaria model. As expected, mRNA levels of the two major proinflammatory cytokines, Il-6 and Tnfa, were significantly enhanced in LPS-treated animals as compared to PBStreated animals (Fig. 3a) . While the levels of Mcp-1 and Rantes mRNAs, as well as mRNAs for the chemokine receptors Darc and Ccr5, were significantly increased in calvaria treated with LPS compared with PBS-treated calvaria (Fig. 3b, c) , the Ccr2 mRNA levels were significantly reduced, and there was no significant change in Ccr1 mRNA levels at 5 h post-LPS injection (Fig. 3c) . Among the four chemokine receptors analyzed in this study, Darc gene showed the greatest change in mRNA expression at 5 h post-LPS injection (Fig. 3c) , suggesting that DARC plays an important role in local inflammatory response induced by LPS injection.
To test the involvement of DARC in response to LPS challenge, we compared mRNA expression of the major inflammatory cytokines, Tnfa and Il-6, as well as Cd14, a marker of macrophages and the most important endotoxin receptor [11, 12] in Darc-KO and WT mice, 24 h post-LPS injection. The mRNA levels of all three genes were (Fig. 4) . However, the magnitude of increase was less in Darc-KO as compared to WT mice (Fig. 4) . This suggests that the lack of Darc expression in Darc-KO mice led to a reduction in the recruitment of inflammatory cells to the inflamed area, reducing the inflammatory response in Darc-KO mice compared with WT mice. To test this prediction, we quantified the macrophage population within the sutures of calvaria bone, using antibody against F4/80, a specific cell surface marker for murine macrophages [13, 14] . At 1 day post-LPS/post-PBS injections, the number of F4/80 positive cells was significantly increased in LPS-treated animals compared with controls for both lines of mice. In contrast, in KO mice there were significantly fewer F4/80-positive cells as compared to WT mice (Fig. 5a, b) . Consistent with the reduced recruitment of macrophage precursors in the LPStreated Darc-KO mice, we found significantly fewer TRAP-positive osteoclasts in response to LPS treatment in Darc-KO mice as compared to WT mice (Fig. 6 ).
Discussion
Inflammatory reactions observed after bacterial infections have been shown to be powerful activators of monocytes and macrophages, and potent inducers of pro-inflammatory cytokines and chemokines known to play a major role in Animals were killed at 24 h post-LPS/post-PBS injection, and gene expression was evaluated by real-time PCR. n = 6-7. Data are presented as fold change vs PBS-treated WT mice ± SEM. *P \ 0.05 vs PBS-treated animals, # LPS-treated WT mice compared with LPS-treated KO mice bone loss. However, the molecular pathways involved in the recruitment of osteoclast precursors in response to inflammation challenge are still not well understood. Since DARC binds to a number of the pro-inflammatory chemokines known to play a major role in inflammatory cell migration as well as bone resorption, we posited that it might also play a critical role in chemokine-induced osteoclast precursor recruitment that leads to bone resorption.
Since DARC is mainly expressed in endothelial cells, we first evaluated the response of DARC to bacterial endotoxin (LPS) challenge in endothelial cells. Our results showed that treatment of the murine endothelial cell line SVEC10-4 with LPS resulted in a significant increase in expression of Darc and Ccr5, as well as the Mcp-1 and Rantes mRNAs by 6 h. Both MCP-1 and RANTES bind to DARC [15] and to their specific receptors, CCR2 and CCR5, respectively. Interestingly, our results also showed that the expression of Ccr2 mRNA was not affected by treatment with LPS. This suggests that interactions between MCP-1/DARC and RANTES/CCR5 are involved in response to LPS challenge.
When DARC function was blocked with anti-DARC antibody in LPS-treated cells, a reduction in the expression of Il-6 and Mcp-1 mRNAs was observed as compared to vehicle-treated cells, suggesting that alteration of MCP-1 binding to DARC mitigates inflammation. This finding strengthens the notion that DARC and MCP-1 play important roles in LPS-induced inflammation. A reduction in the expression of Mcp-1 and Il-6 mRNAs was also Other investigators have reported that DARC is responsible for the chemokine transcytosis from the apical to the basal side of the vascular endothelial membrane [6] . Overall, such reports and our gene profiling data are consistent with the hypothesis that neutralizing DARC function on chemokine transcytosis with anti-DARC antibody reduces chemokine synthesis, which in turn reduces the recruitment of inflammatory cells to the area of LPS injection. To test this hypothesis, the expression of the monocyte marker Cd14 was evaluated post-LPS injection. As predicted, the expression of Cd14 mRNA was found to be reduced in Darc-KO mice compared with WT mice. Furthermore, immunohistochemical experiments revealed a significant reduction in the number of F4/80-positive cells and Trappositive osteoclasts post-LPS injection in KO mice as compared to WT mice, suggesting an important role of DARC-MCP-1 interaction on osteoclast precursor recruitment in response to the local inflammation induced by LPS.
Previous studies [16] have shown that a lack of Ccr5 expression in Ccr5-KO mice led to significant reduction, but not total blockade, in F4/80-positive leukocyte migration following bacterial infection. In the present study, we have observed a significant increase in the expression of Ccr5 mRNA in response to LPS challenge in both SVEC endothelial cells in vitro and mouse calvaria in vivo. However, blocking DARC function in endothelial cells did not affect Rantes mRNA expression, the specific ligand of CCR5, but rather resulted in a decrease in Mcp-1 mRNA expression, the chemokine known to bind to DARC, and a reduction in inflammatory cell infiltration to the area where LPS was injected. Taken together, these data suggest that both DARC-MCP-1 and CCR5-RANTES interactions play an important role in leukocyte migration in response to bacterially induced inflammation.
One of the key regulators of migration and infiltration of monocytes and macrophages is MCP-1 [17] . MCP-1 is also associated with various inflammatory diseases related to bone loss [18, 19] . In Mcp-1-KO mice, it has been shown that a lack of Mcp-1 mRNA expression leads to increased bone mass and a decrease in serum collagen type I fragments (CTX-1), and TRACP 5b [20] . In this study, we have shown that the lack of Darc expression leads to a significant reduction in the expression of Mcp-1 mRNA and a reduction in the number of Trap-positive osteoclasts per unit bone surface area after LPS challenge as compared to WT mice. Based on these data, we have developed a model as to how LPS treatment induces chemokine expression. Since DARC is responsible for the chemokine transcytosis by providing a gradient of chemotactic chemokines to attract osteoclast precursors, our model proposes that blockade of DARC function/expression results in reduced
Mcp-1 expression via feedback mechanism, which in turn leads to a reduction in the recruitment of osteoclast precursors to the site of bacterial infection.
Conclusions
The results of this study showed reduced macrophage recruitment to LPS-treated bone of Darc-KO mice compared with WT mice. This was accompanied by a reduction in the expression of Il-6 and Mcp-1 mRNAs in Darc-KO mice compared with WT mice injected with LPS. In the present study, Darc-KO mice also exhibited reduced TRAP staining on calvaria bone treated with LPS as compared to WT mice, which was likely due to a reduction in the recruitment of inflammatory cells in response to LPS. Taken together, these data suggest that DARC-MCP-1 interaction plays an important role in local bacterial-induced inflammation and subsequent bone resorption.
